CIK 0001811063 · Non-accelerated filer<br>Smaller reporting company
Nuvation Bio Inc.
Sign in to watch- Ticker
- NUVB
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850862255
- Phone
- 332-208-6102
- Business address
- 1 PENNSYLVANIA PLAZA, SUITE 3805, NEW YORK, NY, 10019
- Former names
- Panacea Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $709,240
- in 1 filing, $709K under 10b5-1 plans
Net −$709,240. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-28 | Sjogren Colleen Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-02-28 | Sauvage Philippe Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-02-28 | Markel Stacy CHIEF PEOPLE OFFICER | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-02-28 | Makunje Moses SEE REMARKS | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-02-28 | Liu Dongfang CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-02-28 | Hung David PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +2,000,000 | 2,000,000 | ||
| 2025-02-28 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-02-28 | Hanley David C. CHIEF TECHNICAL OPERATIONS | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2024-11-11 | Wang Junyuan Jerry CEO, ANHEART THERAPEUTICS LTD. | Sale | −56,361 | $2.89 | $163K | 3,866,228 |
| 2024-10-08 | Mashal Robert Director | Purchase | +19 | $2.20 | $42 | 19 |
| 2024-10-08 | Mashal Robert Director | Purchase | +99,981 | $2.20 | $220K | 100,000 |
| 2024-10-07 | Sauvage Philippe Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2024-09-04 | Wang Junyuan Jerry CEO, ANHEART THERAPEUTICS LTD. | Conversion | +2,543,600 | 3,922,589 | ||
| 2024-09-04 | Wang Junyuan Jerry CEO, ANHEART THERAPEUTICS LTD. | Conversion | +1,695,700 | 2,246,458 | ||
| 2024-09-04 | Wang Junyuan Jerry CEO, ANHEART THERAPEUTICS LTD. | Conversion · Series A Preferred Stock | −25,436 | 0 | ||
| 2024-09-04 | Wang Junyuan Jerry CEO, ANHEART THERAPEUTICS LTD. | Conversion · Series A Preferred Stock | −16,957 | 0 | ||
| 2024-09-04 | Cui Xiangmin Director | Conversion | +967,100 | 1,281,206 | ||
| 2024-09-04 | Cui Xiangmin Director | Conversion | +5,157,900 | 7,611,031 | ||
| 2024-09-04 | Cui Xiangmin Director | Conversion | +12,879,200 | 17,062,202 | ||
| 2024-09-04 | Cui Xiangmin Director | Conversion · Series A Preferred Stock | −9,671 | 0 |
Page 6 of 15 · 291 trades